Juno Therapeutics, Inc. (JUNO) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have received an average rating of “Hold” from the nineteen research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $40.04.
Several research firms have recently weighed in on JUNO. Maxim Group reaffirmed a “buy” rating and issued a $56.00 target price (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Juno Therapeutics in a report on Friday, October 6th. Morgan Stanley reiterated an “equal weight” rating and set a $43.00 price target (up previously from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Barclays PLC started coverage on shares of Juno Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price target on the stock. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th.
In other Juno Therapeutics news, EVP Robert Azelby sold 12,850 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total transaction of $577,607.50. Following the transaction, the executive vice president now directly owns 37,439 shares in the company, valued at approximately $1,682,883.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,004 shares of company stock worth $3,551,561. Corporate insiders own 15.26% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Pacad Investment Ltd. acquired a new position in Juno Therapeutics during the 2nd quarter valued at about $105,000. QS Investors LLC acquired a new position in Juno Therapeutics during the 2nd quarter valued at about $135,000. Great West Life Assurance Co. Can lifted its position in Juno Therapeutics by 80.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 3,800 shares during the period. Finally, Macquarie Group Ltd. acquired a new position in Juno Therapeutics during the 2nd quarter valued at about $248,000. Institutional investors own 67.50% of the company’s stock.
Shares of Juno Therapeutics (NASDAQ JUNO) opened at 44.49 on Wednesday. The company’s market capitalization is $4.67 billion. The company has a 50-day moving average of $43.59 and a 200 day moving average of $31.40. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $47.03.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the previous year, the company posted ($0.64) EPS. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. Analysts forecast that Juno Therapeutics will post ($3.08) EPS for the current year.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.